Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms

References

• Hay CR, Palmer B, Chalmers E, et al. United Kingdom haemophilia centre doctors’ organisation (UKHCDO). Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood. 2011;117:6367–6370.
   PubMed Web of Science ®Google Scholar
• Gouw SC, van den Berg HM, Fischer K, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121:4046–4055.
   PubMed Web of Science ®Google Scholar
• Lai J, Hough C, Tarrant J, et al. Biological considerations of plasma-derived and recombinant factor VIII immunogenicity. Blood. 2017;129:3147–3154.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Garagiola I. Product type and other environmental risk factors for inhibitor development in severe hemophilia A. Res Pract Thromb Haemost. 2018;2(2):220–227.
   PubMed Web of Science ®Google Scholar
• Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol. 2013;4(1):59–72.
   PubMedGoogle Scholar
• Rocino A, Franchini M, Coppola A. Treatment and prevention of bleeds in haemophilia patients with inhibitors to factor VIII/IX. J Clin Med. 2017;6(4):E46.
   PubMed Web of Science ®Google Scholar
• Young G. How I treat children with haemophilia and inhibitors. Br J Haematol. 2019;186:400–408.
   PubMed Web of Science ®Google Scholar
• Gouw SC, Fijnvandraat K. Identifying nongenetic risk factors for inhibitor development in severe hemophilia A. Semin Thromb Hemost. 2013;39:740–751.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016;374(21):2054–2064. .
   PubMed Web of Science ®Google Scholar
• Gouw SC, van der Bom JG, Ljung R, et al. PedNet and RODIN study group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013;368:231–239.
   PubMed Web of Science ®Google Scholar
• Collins PW, Palmer BP, Chalmers EA, et al. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000–2011. Blood. 2014;124:3389–3397.
   PubMed Web of Science ®Google Scholar
• Calvez T, Chambost H, Claeyssens-Donadel S, et al. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood. 2014;124:3398–3408.
   PubMed Web of Science ®Google Scholar
• Calvez T, Chambost H, d’Oiron R, et al. Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A. Haematologica. 2018;103(1):179–189. .
   PubMed Web of Science ®Google Scholar
• Rosendaal FR, Palla R, Garagiola I, et al. Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. Blood. 2017;130(15):1757–1759. .
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Factor VIII medicines: no clear and consistent evidence of difference in risk of inhibitor development between classes. Press release 15/09/2017.[cited 2020 Mar 2]. Available from: https://www.ema.europa.eu/en/news/factor-viii-medicines-no-clear-consistent-evidence-difference-risk-inhibitor-development-between
   Google Scholar
• Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18:1570–1574.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Hemlibra (emicizumab). Summary of product characteristics. February 2018. [cited 2019 Dec 30]. Available from: https://www.ema.europa.eu/en/documents/product-information/hemlibra-epar-product-information_en.pdf
   Google Scholar
• US Food and Drugs Administration. Hemlibra (emicizumab-kxwh). Prescribing information. 2017. Nov [cited 2019 Dec 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761083s000lbl.pdf
   Google Scholar
• Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007;109:4648–4654.
   PubMed Web of Science ®Google Scholar
• Matzinger P. The danger model: a renewed sense of self. Science. 2002;296:301–305.
   PubMed Web of Science ®Google Scholar
• Kloosterman FBR, Abdi A, Eckhardt CL, et al. Poster PB0260. Expected timing of initial exposure to factor VIII treatment in non-replacement therapies in hemophilia A. Presented at: International Society on Thrombosis and Haemostasis 2019 Congress; 2019 Jul 6–10; Melbourne, Australia.
   Google Scholar
• Young G. Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance. Blood Adv. 2018;2:2780–2782.
   PubMed Web of Science ®Google Scholar
• Le Quellec S, Negrier C. Emicizumab should be prescribed independent of immune tolerance induction. Blood Adv. 2018;2:2783–2786.
   PubMed Web of Science ®Google Scholar
• Carcao M, Escuriola-Ettingshausen C, Santagostino E, et al. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia. 2019;25:676–684.
   PubMed Web of Science ®Google Scholar
• Batsuli G, Zimowski KL, Tickle K, et al. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis. Haemophilia. 2019;25:789–796.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Emicizumab PUPs and Nuwiq ITI study. [ cited 2019 Dec 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT04030052
   Google Scholar
• Santagostino E, Mancuso ME, Rocino A, et al. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost. 2006;4:367–371.
   PubMed Web of Science ®Google Scholar
• Franchini M, Lippi G, Montagnana M, et al. Anaphylaxis in patients with congenital bleeding disorders and inhibitors. Blood Coagul Fibrinolysis. 2009;20:225–229.
   PubMed Web of Science ®Google Scholar
• Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven comparative (FENOC) study. Blood. 2007;109:546–551.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol. 1999;104:22–26.
   PubMed Web of Science ®Google Scholar
• Teitel J, Berntorp E, Collins P, et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia. 2007;13:256–263.
   PubMed Web of Science ®Google Scholar
• Négrier C, Lienhart A, Numerof R, et al. SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies. Haemophilia. 2013;19:e143–150.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Escobar M, Ozelo M, et al. Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors. Blood Rev. 2015;29(Suppl 1):S9–18. .
   PubMedGoogle Scholar
• Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007;5:1904–1913.
   PubMed Web of Science ®Google Scholar
• Leissinger C, Gringeri A, Antmen B, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011;365:1684–1692.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377:809–818.
   PubMed Web of Science ®Google Scholar
• Mancuso ME, Callaghan MU, Kruse-Jarres R, et al. Emicizumab prophylaxis in adolescent/adult patients with hemophilia A previously receiving episodic or prophylactic bypassing agent treatment: updated analyses from the HAVEN 1 study. Blood. 2017;130(Suppl. 1):1071.
   PubMedGoogle Scholar
• Young G, Liesner R, Chang TY, et al. A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134:2127–2138.
   PubMed Web of Science ®Google Scholar
• Collins PW, Liesner R, Makris M, et al. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving emicizumab. Interim guidance from UKHCDO inhibitor working party and executive committee. Haemophilia. 2018;24(3):344–347. .
   PubMed Web of Science ®Google Scholar
• Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation. MASAC document #255. Recommendation on the use and management of emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors. [ cited 2019 Dec 30]. Available from: https://www.hemophilia.org/sites/default/files/document/files/255Emicizumab.pdf
   Google Scholar
• Pelland-Marcotte MC, Carcao MD. Hemophilia in a changing treatment landscape. Hematol Oncol Clin North Am. 2019;33:409–423.
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med. 2017;377:819–828.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. An open-label extension study of subcutaneously administered fitusiran in patients with moderate or severe hemophilia A or B who have participated in a previous clinical study with fitusiran. [ cited 2019 Dec 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT02554773
   Google Scholar
• Santagostino E, Oldenburg J, Chang T, et al. Surgical experience from four phase III studies (HAVEN 1-4) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors. Presented at: International Society on Thrombosis and Haemostasis 2019 Congress; 2019 Jul 6–10; Melbourne, Australia.
   Google Scholar
• Negrier C, Ragni MV, Georgiev P, et al. ORO8. Perioperative management in patients with hemophilia receiving fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of haemophilia. Haemophilia. 2018;24(S1):1–143.
   Google Scholar